Aduro BioTech Inc (NASDAQ:ADRO) VP Blaine Templeman sold 6,056 shares of Aduro BioTech stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.50, for a total value of $39,364.00. Following the sale, the vice president now directly owns 147,437 shares of the company’s stock, valued at $958,340.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of NASDAQ:ADRO traded up $0.28 on Friday, reaching $6.75. The company had a trading volume of 257,329 shares, compared to its average volume of 282,302. Aduro BioTech Inc has a 52-week low of $5.10 and a 52-week high of $11.55. The company has a market capitalization of $549.47 million, a PE ratio of -4.75 and a beta of 2.23.
Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02. Aduro BioTech had a negative return on equity of 44.97% and a negative net margin of 574.11%. The business had revenue of $2.64 million for the quarter, compared to the consensus estimate of $3.74 million. sell-side analysts forecast that Aduro BioTech Inc will post -1.25 EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in ADRO. Capital Fund Management S.A. purchased a new position in Aduro BioTech during the 2nd quarter worth $130,000. Sofinnova Ventures Inc purchased a new position in Aduro BioTech during the 1st quarter worth $155,000. Legal & General Group Plc grew its stake in Aduro BioTech by 105.3% during the 1st quarter. Legal & General Group Plc now owns 22,233 shares of the biotechnology company’s stock worth $206,000 after buying an additional 11,405 shares during the last quarter. MetLife Investment Advisors LLC grew its stake in Aduro BioTech by 70.6% during the 2nd quarter. MetLife Investment Advisors LLC now owns 31,799 shares of the biotechnology company’s stock worth $223,000 after buying an additional 13,156 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC purchased a new position in Aduro BioTech during the 1st quarter worth $238,000. Hedge funds and other institutional investors own 49.01% of the company’s stock.
A number of research analysts have recently issued reports on ADRO shares. Zacks Investment Research downgraded Aduro BioTech from a “buy” rating to a “hold” rating in a report on Wednesday, July 4th. BidaskClub upgraded Aduro BioTech from a “strong sell” rating to a “sell” rating in a report on Friday, August 31st. HC Wainwright set a $10.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Thursday, August 2nd. Bank of America cut their price target on Aduro BioTech from $8.00 to $6.00 and set an “underperform” rating on the stock in a report on Thursday, August 2nd. Finally, ValuEngine upgraded Aduro BioTech from a “strong sell” rating to a “sell” rating in a report on Friday, June 1st. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $13.67.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Recommended Story: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.